KCNA3 and asthma: This hypothesis developed based on the orally active KV1.3 blocker ICA-17043 (Senicapoc), (Icagen Inc., Durham, NC, USA), which inhibits late airway response and the development of bronchial hyperresponsiveness in sheep-asthma models [170].